Pomalidomide Shows Significant Therapeutic Activity against CNS Lymphoma with a Major Impact on the Tumor Microenvironment in Murine Models

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Li, Zhimin ^a   Qiu, Yushi ^a   Personett, David ^a   Huang, Peng ^a   Edenfield, Brandy ^a   Katz, Jason ^b   Babusis, Darius ^b   Tang, Yang ^b   Shirely, Michael A ^b   Moghaddam, Mehran F ^b   Copland, John A ^a   Tun, Han W ^a  

^a MAYO CLINIC   (United States)

^b CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 4; POMALIDOMIDE; STAT1 PROTEIN; STAT6 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; B CELL LYMPHOMA; BLOOD BRAIN BARRIER; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG PENETRATION; DRUG SCREENING; FEMALE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MACROPHAGE; MACROPHAGE ACTIVATION; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHAGOCYTOSIS; SIGNAL TRANSDUCTION; SURVIVAL RATE; SURVIVAL TIME; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ANGIOGENESIS INHIBITORS; ANIMALS; CELLS, CULTURED; CENTRAL NERVOUS SYSTEM NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; LYMPHOMA; MALE; MICE; MICE, NUDE; RATS; THALIDOMIDE; TUMOR MICROENVIRONMENT; U937 CELLS;

EID: 84881116261     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071754     Document Type: Article

References (18)

1. Ferreri AJ, (2011) How I treat primary CNS lymphoma. Blood 118: 510-522. doi:10.1182/blood-2011-03-321349. PubMed: 21613254.
2. Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, Ottman E, Czuczman MS, (2005) Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res 11: 5984-5992. doi:10.1158/1078-0432.CCR-05-0577. PubMed: 16115943.
3. Zhu D, Corral LG, Fleming YW, Stein B, (2008) Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother 57: 1849-1859. doi:10.1007/s00262-008-0512-7. PubMed: 18392823.
4. Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, Pileri SA, Malik F, et al. (2011) Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer 117: 5058-5066. doi:10.1002/cncr.26135. PubMed: 21495023.
5. Camilleri-Broët S, Crinière E, Broët P, Delwail V, Mokhtari K, et al. (2006) A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood 107: 190-196. doi:10.1182/blood-2005-03-1024. PubMed: 16150948.
6. Rubenstein JL, Treseler PA, Stewart PJ, (2011) Regression of refractory intraocular large B-cell lymphoma with lenalidomide monotherapy. J Clin Oncol 29: e595-e597. doi:10.1200/JCO.2011.34.7252. PubMed: 21519022.
7. Cox MC, Mannino G, Lionetto L, Naso V, Simmaco M, et al. (2011) Lenalidomide for aggressive B-cell lymphoma involving the central nervous system? Am J Hematol 86: 957. doi:10.1002/ajh.22148. PubMed: 21990093.
8. Paxinos G, [!(surname)!], (2001) he mouse brain in stereotaxic coordinates.
9. Wan CP, Park CS, Lau BH, (1993) A rapid and simple microfluorometric phagocytosis assay. J Immunol Methods 162: 1-7. doi:10.1016/0022-1759(93)90400-2. PubMed: 8509646.
10. Jiang L, Marlow LA, Cooper SJ, Roemeling CV, Menke DM, et al. (2010) Selective central nervous system tropism of primary central nervous system lymphoma. Int J Clin Exp Pathol 3: 763-767. PubMed: 21151389.
11. Tun HW, Personett D, Baskerville KA, Menke DM, Jaeckle KA, et al. (2008) Pathway analysis of primary central nervous system lymphoma. Blood 111: 3200-3210. doi:10.1182/blood-2007-10-119099. PubMed: 18184868.
12. Kadoch C, Dinca EB, Voicu R, Chen L, Nguyen D, et al. (2009) Pathologic correlates of primary central nervous system lymphoma defined in an orthotopic xenograft model. Clin Cancer Res 15: 1989-1997. doi:10.1158/1078-0432.CCR-08-2054. PubMed: 19276270.
13. Rubenstein JL, Fridlyand J, Shen A, Aldape K, Ginzinger D, et al. (2006) Gene expression and angiotropism in primary CNS lymphoma. Blood 107: 3716-3723. doi:10.1182/blood-2005-03-0897. PubMed: 16418334.
14. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A, (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23: 549-555. doi:10.1016/S1471-4906(02)02302-5. PubMed: 12401408.
15. Dimopoulos MA, Bartlett JB, Chanan-Khan A, (2006) Immunomodulatory drugs: The emerging treatment paradigm for hematologic malignancies. Highlights from a symposium held during the 10th congress of the European Hematology Association (June/2005).
16. Moussaud S, Draheim HJ, (2010) A new method to isolate microglia from adult mice and culture them for an extended period of time. J Neurosci Methods 187: 243-253. doi:10.1016/j.jneumeth.2010.01.017. PubMed: 20097228.
17. Davies JQ, Gordon S, (2005) Isolation and culture of murine macrophages. Methods Mol Biol 290: 91-103. PubMed: 15361657.
18. Reichlin A, Iizuka K, Yokoyama WM, (2001) Isolation of murine natural killer cells. Curr Protoc Immunol Chapter 3Unit 3.22: Unit 3 22. PubMed: 18432787.